pazopanib
Votrient	Pharmaceutical company: GlaxoSmithKline www.gsk.com

Pharmacologic classification: multi-tyrosine kinase inhibitor
Therapeutic classification: antineoplastic
Pregnancy risk category: D

AVAILABLE FORMS
Tablets: 200 mg, 400 mg

INDICATIONS AND DOSAGES
Advanced renal cell carcinoma—
Adults: 800 mg P.O. daily.
ADJUST-A-DOSE: For moderate hepatic impairment, 200 mg P.O. daily. Drug isn't recommended for patients with severe hepatic impairment.

CONTRAINDICATIONS AND CAUTIONS
Use cautiously in patients with a history of prolonged QT interval, preexisting cardiac disease and in those taking antiarrhythmics or other medications that may prolong the QT interval. Use cautiously in those who are at increased risk for MI, angina, ischemic stroke, and transient ischemic attack (TIA).
   Avoid use in pregnant women and in those who have had an arterial thrombotic event (MI, ischemic stroke), GI bleeding, hemoptysis, or cerebral bleed within the past 6 months.

INTERACTIONS
Drug-drug. CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin): May increase pazopanib concentrations. Avoid using together. If use together is necessary, decrease pazopanib dose.
CYP3A4 inducers (rifampin): May decrease pazopanib levels. Avoid use together.
Drug-food. Grapefruit juice: May increase drug levels. Discourage use together.

ADVERSE REACTIONS
CNS: asthenia, fatigue, headache, TIA.
CV: chest pain, hypertension, MI, prolonged QT interval.
EENT: dysgeusia, epistaxis, hemoptysis.
GI: abdominal pain, anorexia, diarrhea, dyspepsia, nausea, vomiting, rectal hemorrhage.
GU: hematuria, proteinuria.
Hematologic: LEUKOPENIA, LYMPHOCYTOPENIA, NEUTROPENIA, THROMBOCYTOPENIA.
Hepatic: elevated AST and ALT levels, elevated total bilirubin,
Metabolic: decreased glucose, phosphorus, sodium, or magnesium levels, hypothyroidism, increased glucose levels, weight loss.
Respiratory: pulmonary hemorrhage.
Skin: alopecia, hair color change (depigmentation), skin depigmentation, rash.
Other: facial edema, hand-foot syndrome.

Reactions may be common, uncommon, life-threatening, or COMMON AND LIFE-THREATENING.

Home - Guest Registry - Customer Service

Brought to you by Lippincott Williams & Wilkins,
publisher of Lippincott's Nursing Drug Guide.
For help on how you should use this site, see our Disclaimer.

© Copyright 2010 by Lippincott Williams & Wilkins